Deep Experience


Nearly four decades of experience producing high-quality biologics

At Amgen, we specialize in unlocking the potential of biotechnology to create new ways to combat serious diseases to better serve patients. We have been steeped in this challenge since the early days of recombinant DNA technology, when a handful of scientists and investors came together to realize the potential of innovative biotechnology.1

One of our first big discoveries came in 1983. For 2 years, a team led by a young scientist named Fu-Kuen Lin had combed tirelessly through 1.5 million fragments of the human genome before isolating and cloning the erythropoietin gene, which is responsible for the stimulation of red blood cell production. This discovery ultimately set the future direction of our company.2

An early pioneer in biotechnology:

Since 1980, Amgen scientists have been at work developing novel therapies for patients with serious illnesses, including therapeutic proteins such as monoclonal antibodies.1

  • Therapeutic proteins, which replace or supplement beneficial human proteins
  • Monoclonal antibodies: therapeutic proteins that target disease with specificity








These therapies have been used to treat millions of patients around
the world, and there’s an opportunity to help treat millions more with Amgen’s
growing portfolio of biosimilars, both approved and in the pipeline.1–3


Biology first—and foremost

Amgen was one of the first large-scale biotechnology manufacturers, and we’re now one of the largest independent biotechnology companies.4 We have developed some of the most widely used, high-quality biologic medicines, with a portfolio totalling more than a dozen medicines licensed in Canada across several therapeutic areas.5

Each step of the way, we’ve refined our biotechnological processes and expertise. Our long experience developing and refining our systems helps ensure we can provide a reliable supply of our biologic medicines worldwide.2

More recently, we have used human genetic validation whenever possible in the discovery and development process to:1,4,6

  • Pursue a “biology-first” approach to drug discovery—selecting drug targets with a deep understanding of disease biology and then choosing a drug modality, or structural template, best suited to the target.
  • Maintain the industry's leading toolkit of modalities, which allows us to select the optimal tool to target the key molecular defect.

Amgen's “biology-first” approach enables scientists to better determine the appropriate modality to deliver optimal efficacy and safety.1 This leads to:


Enhanced likelihood of success


Efficient development of new medicines


Helps increase new medicine options

Many things at Amgen remain unchanged from those early years. We still operate with the same drive, determination, innovative spirit, and values—finding ways to transform new ideas and discoveries, to help reduce the burden of disease and help make life better for millions of patients worldwide.1


Biosimilar standards born of our
biologics standards

One of our most exciting pursuits is the exploration of biosimilar medicines, which will offer new treatment options for physicians and patients. We are taking our rich biologic experience and putting everything we’ve learned into making high-quality biosimilar medicines. Not only that, we’re backing it all with our established reputation for quality, reliability, and support services.

References: 1. Amgen Fact Sheet. Accessed August 21, 2018. 2. Amgen Corporate Brochure: The Amgen Difference. Accessed August 21, 2018. 3. Health Canada Drug Product Database. 4. Amgen Corporate Brochure: Unlocking the Potential of Biology for Patients. Accessed August 21, 2018. 5. Amgen Canada website. Accessed August 21, 2018. 6. The Shape of Drugs to Come. Published September 19, 2017. Accessed August 21, 2018.

Next: Worldwide Biologics Leader